PF-06273340
- Generic Name
- PF-06273340
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22ClN7O3
- CAS Number
- 1402438-74-7
- Unique Ingredient Identifier
- I136775ABW
- Background
Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)).
- Associated Conditions
- -
- Associated Therapies
- -
Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain Endpoints
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT02260947
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, CL, Netherlands
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT01934738
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01706796
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath